In Brief: Urologix v. BSD
This article was originally published in The Gray Sheet
Urologix v. BSD: Federal district court in Minneapolis grants BSD Medical Corp.'s motion alleging that Urologix, which markets the Targis microwave-based system for benign prostatic hyperplasia, breached the confidentiality provisions of a technology license agreement. The order "did not address other issues of the suit," Urologix says, "including whether BSD was damaged by the breach and whether" its agreement with BSD has been terminated. The suit is scheduled to go to trial "on or after Feb. 16," according to the firm...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.